CAR-T Cell Therapy Manufacturing
Accelerate your CAR-T development program with a manufacturing and development framework built on robust quality systems. Our CDMO capabilities span analytical development, process optimization, and GMP-compliant manufacturing, enabling efficient progression from early development through clinical production while maintaining strict patient safety and regulatory compliance.
We support CAR-T programs through integrated analytical and process development strategies designed to optimize vector transduction, cell expansion, and overall manufacturing scalability. With advanced in-house testing capabilities and state-of-the-art CDMO facilities, we provide comprehensive analytical assay development and quality control to support reliable product characterization and release.
Our flexible CAR-T manufacturing platforms allow developers to implement closed, automated, or hybrid processes during early-phase development, enabling rapid adaptation as programs scale. These customizable manufacturing solutions support both autologous CAR-T and TCR-T cell therapy programs, providing scalable and adaptable production strategies tailored to the specific requirements of each therapeutic pipeline.
Comprehensive CDMO Capabilities for CAR-T Cell Manufacturing
Advance your CAR-T cell therapy programs with integrated CDMO expertise spanning analytical development, process optimization, and GMP-compliant manufacturing. Our multidisciplinary teams support CAR-T development at every stage, enabling efficient scale-up and reliable manufacturing performance throughout the product lifecycle.
With in-house analytical testing capabilities and state-of-the-art CDMO facilities, we deliver rigorous assay development, product characterization, and quality control to support regulatory compliance and consistent manufacturing outcomes.
Our flexible CAR-T manufacturing platforms allow developers to implement closed, automated, or manual processes during early-phase development. These adaptable solutions support both autologous CAR-T and TCR-T programs and can be customized to meet specific process requirements as programs advance toward clinical and commercial production.
Precision-Driven CAR-T Cell Manufacturing
Successful CAR-T manufacturing begins with the efficient isolation of peripheral blood mononuclear cells (PBMCs), which serve as the starting material for T cell enrichment and genetic modification. Leveraging extensive experience in CAR-T process development, we implement optimized workflows to engineer T cells and enhance the functionality and consistency of the resulting CAR-T cell products.
CAR constructs are introduced into T cells using viral vectors, such as lentiviral systems, or through non-viral gene delivery approaches including electroporation. Following gene transfer, CAR expression and product characteristics are confirmed through analytical testing to ensure appropriate receptor expression, cell viability, and product purity.
Our integrated manufacturing processes support efficient cell expansion and cultivation using validated platforms designed to maintain cell quality and functionality. Through streamlined workflows and advanced manufacturing technologies, we enable the reliable production of high yields of viable, CAR-expressing T cells within development timelines suitable for clinical programs.
Robust Technology Transfer for CAR-T Manufacturing
Efficient technology transfer is critical for ensuring seamless progression from development to clinical and commercial manufacturing. Our experienced technology transfer teams support structured process transfer, enabling reproducible manufacturing performance while minimizing operational risk. Through comprehensive documentation, process characterization, and coordinated knowledge exchange, we ensure that critical manufacturing parameters and analytical methods are accurately implemented across development and production environments.
Autologous and Allogeneic CAR-T Manufacturing Solutions
Our CAR-T manufacturing experts provide tailored solutions for both autologous and allogeneic cell therapy programs. Whether developing personalized therapies derived from a patient’s own cells or scalable allogeneic approaches using donor-derived starting materials, our teams support the design and implementation of optimized manufacturing workflows aligned with program-specific requirements.
Ensuring Product Quality and Consistency
Our CDMO facilities operate under rigorous quality systems designed to ensure the safety, purity, and potency of CAR-T cell products. Comprehensive analytical and quality control testing is integrated throughout the manufacturing process, including evaluation of genetic integrity to confirm accurate CAR construct integration and the absence of unintended alterations. These controls support consistent product performance and regulatory compliance across clinical and commercial manufacturing stages.
Scalable CAR-T CDMO Capabilities
Expanding manufacturing capacity is essential to support the increasing demand for CAR-T cell therapies. Our CDMO capabilities incorporate advanced manufacturing technologies, including automated and closed-system platforms, to enable scalable and reproducible CAR-T production. These systems help minimize manual intervention and reduce variability while supporting consistent manufacturing outcomes.
Process optimization strategies—including improved cell culture conditions, transduction efficiency, and downstream purification methods—are implemented to enhance manufacturing efficiency and facilitate reliable scale-up for clinical and commercial supply.
Regulatory Compliance and Quality Systems
Regulatory compliance is fundamental to the development and manufacture of safe and effective cell therapies. Our CAR-T manufacturing programs operate within established quality systems and adhere to global regulatory standards governing analytical development, manufacturing processes, and product testing.
We support the design and implementation of analytical assays aligned with regulatory expectations while ensuring that all manufacturing activities follow Good Manufacturing Practice (GMP) guidelines. In addition, our in-house scientific and regulatory advisory teams monitor evolving regulatory frameworks to help maintain compliance and support efficient progression through clinical development and regulatory review.
Actcell Labs Inc
1361 Amsterdam Ave.,
Floor 3, New York,
NY 10027, USA
+1 888 4880155
support@actcelllabs.com